Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Verve Therapeutics (VERV – Research Report). The associated price target is $21.00.
Cory Jubinville, PhD’s rating is based on the promising progress Verve Therapeutics has made with its VERVE-102 program. The ongoing Phase 1b Heart-2 study has shown that VERVE-102 is well-tolerated with no significant lab abnormalities, providing confidence in the potential for a positive outcome in Q2 2025. This upcoming readout will include initial safety and efficacy data across the first three dose cohorts, which is a critical milestone for the company.
Additionally, Verve’s strategic partnership with Eli Lilly, which includes opt-in rights for the PCSK9 program, strengthens its position in the market. The financial stability of Verve, with $524.3 million on the balance sheet, ensures that the company can continue to reach key milestones. Furthermore, the progress in Verve’s pipeline, including the VERVE-201 program for refractory hypercholesterolemia, adds to the company’s growth potential, making it a compelling buy opportunity.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com